Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IITerminatedD-0855-2022

Drug recall · May 18, 2022

MVASI (bevacizumab-awwb) recall

Why: Defective container: loose crimp defect, potential loss of container integrity.

Class II: could cause temporary or reversible health problems; serious harm is remote.

The recall

Product

MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

Lots / codes

Lots: 1142258, 1143196, Exp. 09/24

Quantity
15,823
Company
Amgen, Inc., Thousand Oaks, CA
Distribution
Nationwide in the USA, Egypt and Lithuania.
Initiated
May 2, 2022 · Voluntary: Firm initiated
Classified
May 9, 2022
Reported
May 18, 2022
Ended
December 2, 2022
How notified
Letter

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.